Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Picton Mahoney Asset Management

Picton Mahoney Asset Management boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 61.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 142 shares of the medical instruments supplier’s stock after purchasing an additional 54 shares during the quarter. Picton Mahoney Asset Management’s holdings in Becton, Dickinson and Company were worth $32,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Wesbanco Bank Inc. boosted its holdings in Becton, Dickinson and Company by 1.9% in the fourth quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock worth $580,000 after purchasing an additional 48 shares during the period. S.A. Mason LLC boosted its holdings in Becton, Dickinson and Company by 3.7% in the fourth quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock worth $321,000 after purchasing an additional 50 shares during the period. Americana Partners LLC boosted its holdings in Becton, Dickinson and Company by 3.5% in the fourth quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier’s stock worth $345,000 after purchasing an additional 52 shares during the period. Novare Capital Management LLC boosted its holdings in Becton, Dickinson and Company by 5.2% in the fourth quarter. Novare Capital Management LLC now owns 1,110 shares of the medical instruments supplier’s stock worth $252,000 after purchasing an additional 55 shares during the period. Finally, Pinnacle West Asset Management Inc. boosted its holdings in Becton, Dickinson and Company by 2.7% in the fourth quarter. Pinnacle West Asset Management Inc. now owns 2,280 shares of the medical instruments supplier’s stock worth $517,000 after purchasing an additional 60 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $227.84 on Tuesday. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $251.99. The firm’s 50-day simple moving average is $232.72 and its 200 day simple moving average is $232.19. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The stock has a market cap of $65.42 billion, a P/E ratio of 37.85, a P/E/G ratio of 1.63 and a beta of 0.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.83%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Becton, Dickinson and Company announced that its Board of Directors has approved a stock repurchase program on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

BDX has been the subject of several analyst reports. Piper Sandler boosted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. Barclays boosted their price target on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday, March 5th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $278.29.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 2,838 shares of the business’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $223.33, for a total value of $633,810.54. Following the sale, the executive vice president now directly owns 6,141 shares in the company, valued at approximately $1,371,469.53. The trade was a 31.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Shan sold 500 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the sale, the executive vice president now owns 5,741 shares in the company, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 7,363 shares of company stock worth $1,676,105 over the last ninety days. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.